Background and Aims: Dual targeted therapy [DTT] has been proposed as a novel therapeutic strategy for the management of complicated patients with inflammatory bowel diseases [IBD]. Our aim here was to investigate the safety and effectiveness of this approach in a real-life setting.Methods: We retrospectively extracted data from IBD patients receiving DTT in Italian IBD referral centres. Baseline characteristics, clinical activity of intestinal and extra-intestinal disease, and C-reactive protein levels were recorded. All adverse events were reported. Clinical effectiveness, biochemical remission and safety of DTT were investigated.Results: Sixteen patients were identified; indications for DTT were: 'active IBD' or 'active EIM' despite ongoing biological therapy. The most commonly used DTT were: vedolizumab + ustekinumab [three patients] and vedolizumab + adalimumab [three patients]. Clinical response of intestinal or extra-intestinal symptoms, according to the indication for DTT, was reported by all patients by the end of the induction. Four patients discontinued DTT during follow-up. Three patients experienced an adverse event; no serious adverse event was reported.Conclusions: DTI seems to be an effective and safe treatment and may represent art appealing therapeutic strategy for the management of complicated IBD patients.

Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease

Ribaldone, Davide Giuseppe;
2021-01-01

Abstract

Background and Aims: Dual targeted therapy [DTT] has been proposed as a novel therapeutic strategy for the management of complicated patients with inflammatory bowel diseases [IBD]. Our aim here was to investigate the safety and effectiveness of this approach in a real-life setting.Methods: We retrospectively extracted data from IBD patients receiving DTT in Italian IBD referral centres. Baseline characteristics, clinical activity of intestinal and extra-intestinal disease, and C-reactive protein levels were recorded. All adverse events were reported. Clinical effectiveness, biochemical remission and safety of DTT were investigated.Results: Sixteen patients were identified; indications for DTT were: 'active IBD' or 'active EIM' despite ongoing biological therapy. The most commonly used DTT were: vedolizumab + ustekinumab [three patients] and vedolizumab + adalimumab [three patients]. Clinical response of intestinal or extra-intestinal symptoms, according to the indication for DTT, was reported by all patients by the end of the induction. Four patients discontinued DTT during follow-up. Three patients experienced an adverse event; no serious adverse event was reported.Conclusions: DTI seems to be an effective and safe treatment and may represent art appealing therapeutic strategy for the management of complicated IBD patients.
2021
15
2
335
339
Biologics; Combination Therapy; Extraintestinal manifestations
Privitera, Giuseppe; Onali, Sara; Pugliese, Daniela; Renna, Sara; Savarino, Edoardo; Viola, Anna; Ribaldone, Davide Giuseppe; Buda, Andrea; Bezzio, Cristina; Fiorino, Gionata; Fantini, Massimo Claudio; Scaldaferri, Franco; Guidi, Luisa; Danese, Silvio; Gasbarrini, Antonio; Orlando, Ambrogio; Armuzzi, Alessandro
File in questo prodotto:
File Dimensione Formato  
Dual Targeted Therapy A Possible Option for the Management.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 204.4 kB
Formato Adobe PDF
204.4 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1878720
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 31
social impact